Principal StatisticianNovo Nordisk A/S, Søborg, DenmarkSøborg, Hovedstaden, Denmark
OC 40.5 - Management of breakthrough bleeding episodes in the phase 3 concizumab studies
Monday, June 24, 202415:45 – 16:00 ICT